関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|
| 反応物 | 8-Chloro-4-methyl-2-phenyl-3,4-dihydropyrido[3,2-F][1,4]oxazepin-5(2H)-one | HCID 59577825 | — |
| 反応物 | 3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)aniline hydrochloride | HCID 67424235 | — |
| 試薬 | Cesium carbonate | HCID 10796 | — |
| 触媒 | 2-(Dicyclohexylphosphino)biphenyl | HCID 2734216 | — |
| 触媒 | Palladium (II) acetate | HCID 4144353 | — |
| 溶媒 | 1,2-Dimethoxyethane | HCID 8071 | — |
| 生成物 | 8-[3-Methoxy-4-(4-methylimidazol-1-yl)anilino]-4-methyl-2-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5-one | HCID 49820086 | 40.02% |
反応手順
were placed in a microwave vial equipped with a stirring bar. The vial was capped and flushed with argon. DME (2 mL) and Et3N (0.028 mL, 0.20 mmol) were added via a syringe and the mixture was stirred at room temperature for 30 min and then heated to 100°C in a microwave apparatus for 1h. The reaction mixture was diluted with dichloromethane and ethyl acetate, fitered and concentrated. The residue was purified by reversed phase HPLC to give 37 mg of the product as a solid.
情報源と証拠
| 出典データセット | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-322a5f0c927a43d5b08115d8443f975d |
|---|
| 出典メモ | 750 AstraZeneca ELN dataset |
|---|
